Stem cell component therapy: Supplementation of unmanipulated marrow with CD34 enriched peripheral blood stem cells

Bone Marrow Transplantation

Volumn 23, Issue 4, 1999, Pages 381-386

  Burt, R K ^a,b   Kuzel, T M ^a   Fishman, M ^a   Brush, M ^a   Villa, M ^a   Welles, C ^a   Rosen, S ^a   Traynor, A E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Wesley Pavilion   (United States)

Author keywords

Allogeneic PBSC transplantation; Engraftment; G CSF; GVHD

Indexed keywords

CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; APLASTIC ANEMIA; ARTICLE; CLINICAL ARTICLE; GRAFT VERSUS HOST REACTION; HUMAN; LEUKAPHERESIS; PERIPHERAL BLOOD STEM CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

EID: 0033006768     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701585     Document Type: Article

References (27)

1. Storek J, Gooley T, Siadak M et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft versus host disease. Blood 1997; 90: 4705-4709.
2. Majolino I, Saglio G, Scime R et al. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Bone Marrow Transplant 1996; 17: 555-560.
3. Urbano-Ispizua A, Garcia-Conde S, Brunet S et al. High incidence of chronic GVHD after allogeneic peripheral blood progenitor cell transplantation from related donors. Blood 1996; 88 (Suppl. 1): 617a.
4. Korbling M, Mirza N, Thall P et al. 100 HLA-identical allogeneic blood stem cell transplantations: the MD Anderson Cancer Center experience. Bone Marrow Transplant 1997; 19 (Suppl. 1): S72.
5. Mills KC, Gross TG, Varney ML et al. Immunologic phenotype and function in human bone marrow, blood stem cells and umbilical blood. Bone Marrow Transplant 1996; 18: 53-61.
6. O'Flaherty E, Sparrow R, Szer J. Bone marrow stromal function from patients after bone marrow transplantation. Bone Marrow Transplant 1995; 15: 207-212.
7. Murphy WJ, Bennett M, Kumar V, Longo DL. Donor-type activated natural killer cells promote marrow engraftment and B cell development during allogeneic bone marrow transplantation. J Immunol 1992; 148: 2953-2960.
8. Storb R, Doney KC, Thomas ED et al. Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients. Blood 1982; 59: 236.
9. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-1672.
10. Korbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma - potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.
11. Bensinger WI, Weaver CH, Appelbaum FR et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655-1658.
12. Brown RA, Adkins D, Goodnough M et al. Allogeneic peripheral blood progenitor cell transplant does not appear to increase the risk of acute GVHD following HLA identical sibling transplant. Blood 1995; 86 (Suppl. 1): 393a.
13. Urbano-Ispizua A, Solano C, Brunet S et al. Allogeneic peripheral blood progenitor cell transplantation: analysis of shortterm engraftment and acute GVHD incidence in 33 cases. Bone Marrow Transplant 1996; 18: 35-40.
14. Schmitz N, Bacigalupo A, Hasenclever D et al. Allogeneic bone marrow vs filgrastim-mobilized peripheral blood progenitor cell transplantation in patients with early leukemia: first results of a randomized multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: 995-1003.
15. Zeng D, Dejbakhsh-Jones S, Strober S. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus host disease: impact on blood progenitor cell transplantation. Blood 1997; 90: 453-463.
16. Bensinger WI, Clift R, Martin P et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blofi 1996; 88: 2794-2800.
17. Russel JA, Brown C, Bowen T et al. Allogeneic blood cell transplants for haematologic malignancy: preliminary comparison of outcomes with bone marrow transplantation. Bone Marrow Transplant 1996; 17: 703-708.
18. + progenitor cells from matched related donors. Bone Marrow Transplant 1996; 18: 1081-1086.
19. + cell content but is associated with delayed pancytopenia. Bone Marrow Transplant 1998; 21: 431-440.
20. Deeg HJ, Lin D, Leisenring W et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft versus host disease: a prospective randomized trial. Blood 1997; 89: 3880-3887.
21. Bachar-Lustig E, Rachmim N, Li HW. Reisner Y. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nature Med 1995; 1: 1268-1273.
22. Rachamim N, Gan J, Segall H et al. Potential role of CD34 stem cells in tolerance induction. Transplant Proc 1997; 29: 1935-1936.
23. + hematopoietic cells. Blood 1996; 88: 2619-2625.
24. + blood cells. Blood 1995; 86: 2500-2508.
25. Hassan HT, Zeller W, Stockschlader M et al. Comparison between bone marrow and G-CSF mobilized peripheral blood allografts undergoing clinical scale CD34 cell selection. Stem Cells 1996; 14: 419-429.
26. Nemunaitis J, Albo V, Zeigler ZR et al. Reduction of allogeneic transplant morbidity by combining peripheral blood and bone marrow progenitor cells. Leuk Lymphoma 1993; 10: 405-406.
27. Aversa F, Terenzi A, Tabilio A et al. Addition of PBSCs to the marrow innoculum allows engraftment of mismatched T cell depleted transplants for acute leukemia. Bone Marrow Transplant 1996; 17: (Suppl. 2): S58-S61.